Growth hormone-induced alterations in the insulin-signaling system.
Growth hormone (GH) counteracts insulin action on lipid and glucose metabolism. However, the sequence of molecular events leading to these changes is poorly understood. Insulin action is initiated by binding of the hormone to its cell surface receptor (IR). This event activates the intrinsic tyrosine kinase activity residing in the beta-subunit of the IR and leads to autophosphorylation of the cytoplasmic portion of the beta-subunit and further activation of its tyrosine kinase towards several intermediate proteins, including the family of IR substrates (IRS) and the Shc proteins. When tyrosine phosphorylated, these cellular substrates connect the IR with several downstream signaling molecules. One of them is the enzyme phosphatidylinositol (PI) 3-kinase. The insulin antagonistic action of GH is not a consequence of a direct interaction with the IR. Instead, long-term exposure to GH is, in general, associated with hyperinsulinemia, which leads to a reduction of IR levels and an impairment of its tyrosine kinase activity. The signals of GH and insulin may converge at post-receptor levels. The signaling pathway leading to activation of PI 3-kinase appears to be an important site of convergence between the signals of these two hormones and seems to be mediated principally by IRS-1. Rodent models of chronic GH excess have been useful tools to investigate the mechanism by which GH induces insulin resistance. Decreased IR, IRS-1, and IRS-2 tyrosyl phosphorylation in response to insulin was found in skeletal muscle, whereas a chronic activation of the IRS-PI 3-kinase pathway was found in liver. The induction of the expression of proteins that inhibit IR signaling such as suppressors of cytokine signaling (SOCS)-1 and -6 may also be involved in this alteration. Interestingly, the modulation of insulin signaling and action observed in states of GH excess, deficiency, or resistance seems to be relevant to the changes in longevity associated with those states.
Dominici
Fernando P
FP
Instituto de Química y Fisicoquímica Biológicas (UBA-CONICET), Facultad de Farmacia y Bioquímica, Junin 956 (1113), Buenos Aires, Argentina.
Turyn
Daniel
D
D000818:Animals; D003920:Diabetes Mellitus / Q000378:metabolism / Q000503:physiopathology; D013006:Growth Hormone / Q000502:physiology*; D006801:Humans; D007328:Insulin / Q000502:physiology*; D011972:Receptor, Insulin / Q000502:physiology*; D011986:Receptors, Somatotropin / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
D007328:Insulin; D011986:Receptors, Somatotropin; D013006:Growth Hormone; D011972:Receptor, Insulin